$61.81
5.26% yesterday
Nasdaq, Jun 02, 09:47 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

ANI Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
88%
Hold
13%

ANI Pharmaceuticals, Inc. Price Target

Target Price $82.63
Price $61.91
Potential
Number of Estimates 8
8 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2026 . The average ANI Pharmaceuticals, Inc. target price is $82.63. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the ANI Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 614.38 785.78
26.20% 27.90%
EBITDA Margin 11.49% 25.48%
48.17% 121.83%
Net Margin -3.28% 4.24%
203.14% 229.28%

8 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2025 . The average ANI Pharmaceuticals, Inc. sales estimate is

$786m
Unlock
. This is
3.17% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$797m 1.84%
Unlock
, the lowest is
$770m 5.15%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $614m 26.20%
2025
$786m 27.90%
Unlock
2026
$843m 7.28%
Unlock
2027
$895m 6.19%
Unlock
2028
$916m 2.30%
Unlock
2029
$969m 5.82%
Unlock

7 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2025. The average ANI Pharmaceuticals, Inc. EBITDA estimate is

$200m
Unlock
. This is
67.32% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$203m 69.41%
Unlock
, the lowest is
$194m 62.35%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $70.6m 34.59%
2025
$200m 183.69%
Unlock
2026
$224m 12.10%
Unlock
2027
$255m 13.54%
Unlock
2028
$262m 2.82%
Unlock
2029
$290m 10.66%
Unlock

EBITDA Margin

2024 11.49% 48.17%
2025
25.48% 121.83%
Unlock
2026
26.62% 4.47%
Unlock
2027
28.47% 6.95%
Unlock
2028
28.61% 0.49%
Unlock
2029
29.92% 4.58%
Unlock

4 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average ANI Pharmaceuticals, Inc. net profit estimate is

$33.3m
Unlock
. This is
617.39% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$46.6m 823.45%
Unlock
, the lowest is
$24.3m 476.86%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-20.2m 230.17%
2025
$33.3m 265.36%
Unlock
2026
$59.2m 77.55%
Unlock
2027
$102m 73.07%
Unlock
2028
$123m 20.53%
Unlock
2029
$138m 11.68%
Unlock

Net Margin

2024 -3.28% 203.14%
2025
4.24% 229.28%
Unlock
2026
7.02% 65.57%
Unlock
2027
11.44% 62.96%
Unlock
2028
13.48% 17.83%
Unlock
2029
14.22% 5.49%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.04 1.54
222.35% 248.08%
P/E 40.27
EV/Sales 2.30

4 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. EPS is

$1.54
Unlock
. This is
581.25% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.15 771.88%
Unlock
, the lowest is
$1.12 450.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.04 222.35%
2025
$1.54 248.08%
Unlock
2026
$2.73 77.27%
Unlock
2027
$4.73 73.26%
Unlock
2028
$5.70 20.51%
Unlock
2029
$6.36 11.58%
Unlock

P/E ratio

Current -193.47 571.00%
2025
40.27 120.81%
Unlock
2026
22.68 43.68%
Unlock
2027
13.10 42.24%
Unlock
2028
10.87 17.02%
Unlock
2029
9.73 10.49%
Unlock

Based on analysts' sales estimates for 2025, the ANI Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.23 18.01%
2025
2.30 3.22%
Unlock
2026
2.15 6.78%
Unlock
2027
2.02 5.83%
Unlock
2028
1.98 2.25%
Unlock
2029
1.87 5.50%
Unlock

P/S ratio

Current 1.65 37.15%
2025
1.71 3.27%
Unlock
2026
1.59 6.79%
Unlock
2027
1.50 5.83%
Unlock
2028
1.46 2.24%
Unlock
2029
1.38 5.50%
Unlock

Current ANI Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Guggenheim
Locked
Locked
Locked May 12 2025
Truist Securities
Locked
Locked
Locked Apr 21 2025
Guggenheim
Locked
Locked
Locked Apr 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 17 2025
Jefferies
Locked
Locked
Locked Mar 14 2025
JP Morgan
Locked
Locked
Locked Mar 12 2025
Guggenheim
Locked
Locked
Locked Mar 05 2025
Analyst Rating Date
Locked
Guggenheim:
Locked
Locked
May 12 2025
Locked
Truist Securities:
Locked
Locked
Apr 21 2025
Locked
Guggenheim:
Locked
Locked
Apr 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 17 2025
Locked
Jefferies:
Locked
Locked
Mar 14 2025
Locked
JP Morgan:
Locked
Locked
Mar 12 2025
Locked
Guggenheim:
Locked
Locked
Mar 05 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today